Thromboprophylaxis by Low Molecular Heparin During the Post-partum Period — THROM-PP2021  

Thromboembolic Disease Clinical Trial

Official title: Adherence Between Thromboprophylaxis Prescriptions and Guidelines During the Post-partum Period After the Institution of a Local Protocol

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the current level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol during the post-partum period. The institutional protocol is based on national and international guidelines.

Clinical Trial Description

Venous thromboembolism (VTE) became the 4th cause of maternal mortality and the 2nd direct cause of maternal mortality in France.

The re are only few randomized studies on the thromboprophylaxis during the post-partum period. This expose some discrepancy between French guidelines, French Society of Anesthesia & Intensive Care Medecine (SFAR) and National College of French Gynecologists and Obstetricians (CNGOF ).

The duration and adequate dose of low molecular heparin prescriptions are unclear.

The level of adequacy of thromboprophylaxis prescriptions at Centre Hospitalier Sud Francilien with the SFAR recommendations appears to be less than 50 % in a preliminary unpublished study.

Since this assessment, institutional protocol synthesizing thromboprophylaxis guidelines during the post-partum was exposed and validated among medical staff (both anaesthesiologists ang obstetricians). ;

Related Conditions & MeSH terms

• Thromboembolic Disease
• Thromboembolism

• NCT number: NCT04883385
• Study type: Observational
• Source: Centre Hospitalier Sud Francilien
• Status: Completed
• Start date: October 8, 2021
• Completion date: July 9, 2022